The modern, dynamically developing Russian pharmaceutical company, one of the leaders in the pharmaceutical industry of the Russian Federation in terms of growth rates.
The company's turnover amounted to more than 44.2 billion rubles by 2023 with growth more than 120%.
Skopinpharm is a developer and manufacturer of medicines, one of the leading suppliers under the program of 14 high-cost nosologies in accordance with the Ministry of Health of the Russian Federation orders. Skopinpharm offers a range of medications under the regional preferential insurance program, and is also one of the main suppliers of the Circle of Good Foundation for helping children with serious and life-threatening illnesses.
The company has been implementing two Special Investment Contracts: for the production of drugs from blood plasma and for the treatment of oncological diseases. As part of the implementation of these two contracts, new production and warehouse buildings are being built, unique technologies for the production of medicines are being transferred, a plasma storage facility with a laboratory is being built, which will provide storage of plasma for fractionation (raw materials for the production of medicines from human blood plasma). At the same time, in partnership with health authorities, a modern system for the procurement of blood plasma is being created and a voluntary donation program is being developed.
Skopinpharm actively supports the training and advanced training of pharmaceutical industry specialists and is one of the founders of the Academy of Good Practices of the EAEU.
The successes of Skopinpharm have been repeatedly noted by the Russian Union of Industrialists and Entrepreneurs for “Dynamic Business Development” and “For the Import Substitution Project”, awards from the Governor, the Administration and the Association of Employers of the Ryazan Region.